| Identification | Back Directory | [Name]
N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-(2,2,2-trifluoroethyl)-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide | [CAS]
1835667-63-4 | [Synonyms]
CPD0557
Befotertinib
lung,Epidermal growth factor receptor,D0316,D 0316,ErbB-1,Inhibitor,HER1,inhibit,cancer,EGFR,kinase,tyrosine,non-small,NSCLC
N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-(2,2,2-trifluoroethyl)-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide
2-Propenamide, N-[2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-[1-(2,2,2-trifluoroethyl)-1H-indol-3-yl]-2-pyrimidinyl]amino]phenyl]- | [Molecular Formula]
C29H32F3N7O2 | [MOL File]
1835667-63-4.mol | [Molecular Weight]
567.61 |
| Chemical Properties | Back Directory | [density ]
1.26±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 62.5 mg/mL (110.11 mM; ultrasonic and warming and heat to 60°C) | [form ]
Solid | [pka]
12.68±0.70(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Uses]
Befotertinib (D-0316) is the third-generation EGFR tyrosine kinase inhibitor. Befotertinib can be used for the research of EGFR T790M-positive non-small cell lung cancer (NSCLC)[1]. | [References]
[1] Nagasaka M, et, al. Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors For Advanced EGFR+ NSCLC. J Thorac Oncol. 2021 May;16(5):740-763. DOI:10.1016/j.jtho.2020.11.028 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
|